Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2

Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2

Objectives: This study aims to examine whether the parenterally administered mRNA-based COVID-19 vaccines can induce sufficient mucosal-type IgA responses to prevent SARS-CoV-2 transmission. Methods: We examined the longitudinal kinetics of SARS-CoV-2 spike RBD-specific IgA and IgG responses in sera...

Full description

Bibliographic Details
Main Authors:	Michinobu Yoshimura, Atsuhiko Sakamoto, Ryo Ozuru, Yusuke Kurihara, Ryota Itoh, Kazunari Ishii, Akinori Shimizu, Bin Chou, Yusuke Sechi, Aya Fujikane, Shigeki Nabeshima, Kenji Hiromatsu
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Heliyon
Subjects:	SARS-CoV-2 BNT162b2 Breakthrough infection IgA mRNA vaccination
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023108036

Similar Items

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan
by: Atsuhiko Sakamoto, et al.
Published: (2022-05-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022-01-01)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
by: Su Lan Yang, et al.
Published: (2022-12-01)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2022-12-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines
by: Michinobu Yoshimura, et al.
Published: (2024-02-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022-06-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
by: Louise Murdoch, et al.
Published: (2023-09-01)

Rapid progression of marginal zone B-cell lymphoma after COVID-19 vaccination (BNT162b2): A case report
by: Akinori Sekizawa, et al.
Published: (2022-08-01)

Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
by: Jun Otani, et al.
Published: (2021-10-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Kinetics of SARS-CoV-2 Spike Antibodies after the Second and Third Dose of the BNT162b2 COVID-19 Vaccine and Association with Epidemiological Characteristics and Breakthrough Infection in a Cohort Study of Healthcare Workers
by: Elizabeth-Barbara Tatsi, et al.
Published: (2023-08-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022-11-01)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
by: Erdal Yavuz, et al.
Published: (2022-04-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
by: Mohammad Shehab, et al.
Published: (2021-11-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
by: Flavia Beccia, et al.
Published: (2023-02-01)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
by: Gilbert T. Chua, et al.
Published: (2022-12-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

To vaccinate or not to vaccinate – BNT162b2 seroconversion rate and side effects among Polish healthcare workers
by: Bartosz Siewert, et al.
Published: (2022-09-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
by: Ivan Odak, et al.
Published: (2024-01-01)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine
by: Andrea Lombardi, et al.
Published: (2022-01-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
by: Erez Bar-Haim, et al.
Published: (2022-05-01)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
by: Rui Li, et al.
Published: (2022-06-01)

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
by: Maria Costantino, et al.
Published: (2022-03-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
by: Efrén Murillo-Zamora, et al.
Published: (2021-07-01)